In a unique partnership with three image reading centres located in The Queen’s University of Belfast, St Paul’s Eye Unit, Liverpool and Moorfields Eye Hospital, London, the company’s Clinical Trials iP software will enable healthcare staff to analyse digital images of the retina gathered from some 3,000 patients per annum, over the next four years, in 50 regional eye units across the UK.
The results from this study will be used to measure the effectiveness of a specialist drug and laser therapy (Verteporfin Photodynamic Therapy) as a treatment for patients suffering from “wet” age-related macular degeneration (AMD), a disease of the retina that is a common cause of blindness. The nationwide study could also serve as a model for future programmes to monitor healthcare treatments.
The Clinical Trials iP software is a sophisticated electronic platform that combines the capacity to handle the huge volumes of imaging data captured to diagnose and treat “wet” AMD, with an electronic patient care management system. After reading centre staff have used the system to import thousands of retinal images, they can electronically transfer the data between a network of computers for grading using a secure telemessaging facility.
Professor Usha Chakravarthy of the Centre for Vision Science at Queen’s University, Belfast and Ophthalmic Consultant at Belfast’s Royal Hospitals, is one of the lead clinical investigators involved in delivering treatment for patients with “wet” AMD.
Professor Chakravarthy said: “This is a defining moment in the introduction of new technologies in that it will provide robust findings on the long-term benefits of verteporfin photodynamic therapy for the “wet” form of age-related macular degeneration, which afflicts several thousand older adults annually.”
So far, over 5,000 images or angiograms from over 3,000 patients have been submitted in digital and film formats from the 50 regional treatment centres to the Central Angiographic Resource Facility (CARF) in Belfast and imported into Digital Healthcare’s Clinical Trials iP software.
Dr Liam Patton of Queen’s University, Belfast and a manager at the CARF, said: “A key strength of the Clinical Trials iP software is that it enables images captured from a variety of sources to be standardised and graded on a common platform. We can accept angiograms from almost any ophthalmic imaging system in use in the UK, and we also import film images. We can then use a secure electronic telemessaging system to transfer the images to the Reading Centres for grading.
The software has eliminated the need to use paper-based systems previously used for this type of work. During the grading process there are a multitude of tools available to assist grading staff in arriving at their decisions, including grids, circles and measurement tools so that graders can manipulate and compare images. The software also includes a built-in facility to highlight “urgent” patients so that they can be promptly graded and their results transferred to a treatment centre for further investigations.”
Nick Nightingale, Applications Director at Digital Healthcare, said: “We are delighted to have been selected to provide the software for this groundbreaking study that will generate vital information to improve treatments for patients suffering from AMD, and which could also serve as a model for the assessment of new healthcare technologies.
We have worked closely with the CARF and the three reading centres to test and perfect the Clinical Trials iP software. Healthcare staff now have a fully-automated, electronic information system that can perform a multitude of tasks from importing a range of images, distributing them for grading and managing the selection and quality assurance processes, right through to sending the data results to the Department of Public Health Policy in London.”
Efficient time synchronization of sensor networks by means of time series analysis
24.01.2017 | Alpen-Adria-Universität Klagenfurt
Ultra-precise chip-scale sensor detects unprecedentedly small changes at the nanoscale
18.01.2017 | The Hebrew University of Jerusalem
A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...
For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.
According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
24.01.2017 | Physics and Astronomy
24.01.2017 | Life Sciences
24.01.2017 | Health and Medicine